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Background: Device therapy is an established therapy for preventing sudden cardiac death or managing
refractory congestive heart failure in adults. However, it is performed less commonly in pediatric
populations. This review aimed to examine the indications and problems associated with implantable
cardioverter-deﬁbrillator (ICD) and cardiac resynchronization therapy (CRT) device implantations in
pediatric and congenital heart disease (CHD) patients.
Results: In a multicenter study in Japan, the cardiac condition of CHD patients improved by 83% after CRT
device implantation. The need for CRT devices is more common in children than in adults. After ICD
implantation, 44% of the patients experienced appropriate shocks, and epicardial lead implantation was
performed in one-third of the patients. Nonendocardial electrode placement is mandatory for ICD
implantation in small infants and patients with certain CHDs. Although inappropriate ICD discharges due
to sinus tachycardia or other supraventricular tachycardias are common in children, the indication for
ICD implantation may be higher than that reported in children.
Conclusions: Despite the limited experience, limitations of device implantations owing to the size of the
devices, and necessity for nonendocardial electrode placement, device implantations are required in
more pediatric and CHD patients than expected.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Device therapy is a well-established treatment for preventing
sudden cardiac death or managing drug-refractory congestive heart
failure in adults [1–6]. However, device therapy is performed less
commonly in pediatric populations, and the indications for implan-
table cardioverter-deﬁbrillator (ICD) or cardiac resynchronization
therapy (CRT) device implantations are unclear in pediatric patients.
This review aimed to examine the indications for ICD and CRT device
implantations in pediatric and congenital heart disease (CHD) patients.
2. Present situation of device therapy in Japan
In a multicenter survey of device therapy performed before
2012 in Japanese children [7], the most frequent indications for
device therapy included hypertrophic cardiomyopathy, long QT
syndrome, and catecholaminergic polymorphic ventricular tachy-
cardia for ICD patients and dilated cardiomyopathy (DCM), cardiac
failure due to right ventricular pacing in congenital complete
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atrioventricular block, polysplenia, asplenia, tetralogy of Fallot, and
atrioventricular septal defect for patients with CRT with a biven-
tricular pacemaker (CRT-P) and those with CRT with a dual-
chamber (DDD) pacemaker (CRT-DDD). DCM was the most com-
mon condition that required CRT with a deﬁbrillator (CRT-D).
ICD, CRT-DDD, CRT-P, and CRT-D implantations were performed in
64 (42%), 47 (31%), 34 (22%), and 7 (5%) of 152 patients, respectively.
Among 81 CRT-P and CRT-DDD patients, CRT-DDD was used in
41% of the patients at general hospitals vs. 89% at children’s
hospitals (Fig. 1). Furthermore, CRT-DDD and CRT-P were effective
in improving heart failure in 67 patients (83%). These results show
that the number of CRT-P and CRT-D implantations needed in
children may be higher than that believed previously. In contrast
to general hospitals, children’s hospitals have no choice but to use
DDD pacemakers for CRT, because CRT-P devices are not allowed
to be used for biventricular CRT-P. In Japan, the institutional
criteria for CRT implantation are as follows:
(1) The hospital should have both cardiology and cardiovascular
surgery departments.
(2) The hospital should perform more than 50 electrophysiologi-
cal studies (EPS) per year, and more than 5 of these EPS should
focus on ventricular arrhythmias.
(3) The hospital should perform more than 50 open-heart sur-
geries or aortocoronary bypass surgeries per year and more
than 10 pacemaker implantations per year.
(4) The hospital should have extensive experience in treating
severe congestive heart failure using internal or external
ventricular assist devices.
(5) More than 2 fulltime cardiologists and cardiovascular surgeons
should be employed by the hospital, and more than 2 doctors
should have undergone authorized training for CRT device
implantations.
(6) The hospital should have adequate instruments for blood tests,
biochemical examinations, and diagnostic imaging.
The institutional criteria for ICD and CRT-D implantations are as
follows:
(1) The hospital should have both cardiology and cardiovascular
surgery departments.
(2) The hospital should perform more than 50 EPS per year, and
more than 5 of these EPS should focus on ventricular
arrhythmias.
(3) The hospital should perform more than 50 open-heart sur-
geries or aortocoronary bypass surgeries per year and more
than 10 pacemaker implantations per year.
(4) More than 2 fulltime cardiologists and cardiovascular surgeons
should be employed by the hospital, and more than 2 doctors
should have undergone authorized training for CRT device
implantations.
(5) The hospital should have adequate instruments for blood tests,
biochemical examinations, and diagnostic imaging.
Almost none of the children’s hospitals met criteria (2) and
(3) for CRT device implantations and criterion (2) for ICD and CRT-
D implantations. On the other hand, the institutional criteria for
pacemaker implantations include that more than 1 fulltime car-
diologist and cardiovascular surgeon with 45 years’ experience in
cardiology or cardiovascular surgery should be employed by the
hospital. Therefore, owing to the government criteria requiring
Fig. 1. Pediatric use of ICD, CRT-D, CRT-P, and CRT-DDD over the past 13 years [7]. ICD, CRT-DDD, CRT-P, and CRT-D implantations were performed in 64 (42%), 47 (31%), 34
(22%), and 7 (5%) cases, respectively, in the participating hospitals (A). Of CRT-P and CRT-DDD implantations, CRT-DDD implantations accounted for 96% of the therapy used
in children’s hospitals (B) vs. 41% in general hospitals (C). CRT-D, cardiac resynchronization therapy with a deﬁbrillator; CRT-P; cardiac resynchronization therapy with a
biventricular pacemaker; CRT-DDD, cardiac resynchronization therapy with a dual-chamber (DDD) pacemaker; ICD, implantable cardioverter-deﬁbrillator.
N. Sumitomo / Journal of Arrhythmia 30 (2014) 428–432 429
regulatory approval for those devices, CRT-P is not covered by the
National Health Insurance at children’s hospitals.
Given the promising role of CRT in CHD treatment in addition
to the 83% improvement rate in cardiac condition after CRT-P and
CRT-DDD implantations and the increasing demand for pediatric
CRT especially in preschool-age children, it is crucial that CRT-Ps
become available for children. The need for CRT-Ps is more
common in children than in adults.
Of 64 ICD patients, 28 (44%) experienced appropriate shocks,
and 19 (29%) experienced inappropriate shocks (Fig. 2). This may
also suggest that the number of patients with an indication for ICD
implantation may be higher than that reported in children.
Lead implantation in children also differs from that in adults. The
Japanesemulticenter survey [7] showed that of 152 patients, epicardial
leads were used in 94 (62%), transvenous leads were used in 53 (35%),
and both leads were used in 5 (3%) patients. Epicardial leads were
used in approximately two-thirds of the patients and in almost all of
the patients aged o9 years. Moreover, epicardial leads were used for
most of the CRT patients, regardless of their age or bodyweight.
However, the use of transvenous leads for ICD implantations was
higher in patients 48 years of age or with a bodyweight of 430 kg.
Epicardial lead implantation was performed in approximately one-
third of the patients, and left subcutaneous lead implantation was
performed in most of the patients.
3. Associated heart disease in children with ICD implantations
In a multicenter ICD registry of 443 patients [8], 69% of the patients
had CHD and 23% had cardiomyopathy. The most common heart
disease was tetralogy of Fallot (19%), followed by hypertrophic
cardiomyopathy (14%) (Fig. 3). In structurally normal hearts, long QT
syndrome was the most prevalent disease, and it accounted for 31% of
the heart disease cases including Brugada syndrome and catechola-
minergic polymorphic ventricular tachycardia (Fig. 4).
4. ICD placement in children
ICD placement in teenagers and those with anatomically normal
hearts may not differ from that in adults. However, in young patients,
the size of the ICD generator and the growth rates and activity levels of
the patients should be considered. Given the long life expectancy of
children, those with ICD implantations may need complex lead
extractions and multiple lead replacements. Development of venous
occlusions and the potential risk of thromboembolisms should also be
considered in patients with intracardiac shunts. In the treatment of
some CHDs or postoperative CHDs using the Glenn procedure or
extracardiac total cavopulmonary connection, transvenous lead place-
ment is often impossible.
Consequently, nonendocardial electrode placement is mandatory
for ICD implantations in small infants and patients with certain CHDs.
No subcutaneous arrays or patches are available at present, and in
most studies [9–12], the ICD shock leads were placed either in the
pericardial space or subcutaneously (Fig. 5). The advantages and
disadvantages of these lead routes are listed in Table 1. Furthermore,
nontransvenous ICD systems reportedly survive for a signiﬁcantly
shorter time than do transvenous ICD systems [13].
Nontransvenous ICD systems are now available [14,15]; how-
ever, they are not suitable for small children, because the size of
the generator is very large.
Table 2 lists the ICD system-related complications [16]. Because
of sinus tachycardia or other supraventricular tachycardias, nearly
50% of children with ICD implantations have inappropriate ICD
discharges. Depression or anxiety associated with ICD discharges is
another problem in children.
5. Criteria for ICD implantations in children
The indications for ICD implantations in children were primary
prevention in 52% and secondary prevention in 48% of the
Fig. 2. Outcomes after ICD implantation [7]. Nineteen patients (30%) experienced
appropriate but not inappropriate shocks, 9 (14%) experienced both appropriate
and inappropriate shocks, and 10 (16%) experienced inappropriate but not appro-
priate shocks. Twenty-six children (41%) experienced no shocks. Overall, approxi-
mately one-third of the ICD patients experienced inappropriate shocks.
Fig. 3. Anatomic diagnoses of pediatric and CHD ICD recipients [8]. Struct Normal,
structurally normal hearts; TOF, tetralogy of Fallot; TGA, transposition of the great
arteries; Single V, single ventricle; CHD, congenital heart disease; Coronary Anom,
coronary anomaly; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyo-
pathy; ARVC, arrhythmogenic right ventricular cardiomyopathy; LVNC, left ven-
tricular noncompaction; RCM, restrictive cardiomyopathy.
Fig. 4. Electrical diagnoses of pediatric ICD recipients with structurally normal
hearts [8]. LQTS, long QT syndrome; Idio VF, idiopathic ventricular ﬁbrillation;
CPVT, catecholaminergic polymorphic ventricular tachycardia; Brugada, Brugada
syndrome; VT, ventricular tachycardia; NOS, not otherwise speciﬁed; Cond sys dz,
conduction system disease; WPW, Wolff–Parkinson-White syndrome; AVB,
atrioventricular block.
N. Sumitomo / Journal of Arrhythmia 30 (2014) 428–432430
patients. Single-chamber ICDs were implanted in 42%, and DDD-
ICDs were implanted in 58% of the patients. The suggested retro-
spective indication criteria for ICD implantations in children [17]
are listed in Tables 3 and 4.
6. CRT in pediatric and CHD patients
In a multicenter retrospective study of CRT in pediatric and
CHD patients [18], the underlying heart diseases were CHD in 71%,
cardiomyopathy in 6%, and congenital complete atrioventricular
block in 13% of the patients. Cecchin et al. [19] reported that 77% of
patients in their institute underwent CRT, and idiopathic dilated
cardiomyopathy was observed in 17%.
Fig. 5. Various ICD lead placement methods in children. (A) Transvenous lead implantation with the lead looped or curved in the right ventricle to allow for a sufﬁcient
length of the lead to account for the growth of the child. (B) Epicardial lead implantation [10]. (C) Lead implantation posteriorly behind the heart and superiorly toward the
transverse sinus by a subxiphoid incision through a pericardial window [11]. (D) Lead implantation in a substernal position with the ICD placed in the left abdomen. (E) Lead
implantation in a left subcutaneous position with the ICD placed in the right abdomen. (F) Endocardial lead implantation through the right atrial appendage [12].
Table 1
Implantable cardioverter-deﬁbrillator lead route options in pediatric patients [9].
Advantages Disadvantages
Transvenous Relatively easy to use; common use; approved
indication
Lead fractures; extraction difﬁcult; vascular obstruction
Epicardial patch Long history, follow-up; approved use; surgeons
familiar with its use; good DFT
Patch failure; buckling; restrictive pericardial physiology
Subcutaneous array or coil No transvenous coil or epicardial patch; minimally
invasive
Limited long-term data; higher DFT
Pericardial coil No need for transvenous access or epicardial patch; low
DFT
Requires surgeon; adhesions may limit video-assisted thoracoscopic
surgery; limited follow-up data
Subcutaneous leadless implantable
cardioverter-deﬁbrillator
No need for transvenous or epicardial access;
minimally invasive
Limited long-term data; higher DFT; no chronic pacing or
antitachycardia pacing
DFT¼deﬁbrillation threshold.
Table 2
ICD system-related complications in children [16].
Inappropriate ICD therapy: 11–50%, owing to sinus tachycardia,
supraventricular tachycardia, lead failures, T-wave oversensing, and QRS
complex double sensing
Lead failures: 7–30% (youngest and smallest patients; with growth, the
proximal shock electrode tends to become stretched and distorted)
Depression and/or anxiety: 44%
Increase in deﬁbrillation threshold: failure of the ﬁrst ICD shock in 7%
Electrical storm
Patient death: sudden death (4%), death due to recurrent ventricular
arrhythmias (1%)
Table 3
Secondary prevention in pediatric and CHD patients [17].
Class I
Aborted SCD without reversible cause
Sustained ventricular tachycardia (VT) associated with structural heart disease
Hemodynamically signiﬁcant sustained VT without reversible cause or
potential cure
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In a previous study [18], the mean QRS duration before CRT was
166.1733.3 ms, and it decreased to 37.7730.7 ms (po0.01) after
CRT. In this study, the systemic ventricular ejection fraction before
CRT was 26.2711.6%, and it increased to 39.9714.8% (po0.05)
after CRT. This improvement did not differ among the types of
heart disease (Table 5).
Cecchin et al. [19] reported that of 18 patients listed for heart
transplantation, the condition of 3 patients improved sufﬁciently
and they were removed from the heart transplant list, 5 underwent
heart transplantation, 2 died, and 8 others are awaiting a heart
transplant after CRT.
Although data are limited, these studies show that CRT is an
effective therapy in CHD patients and children with cardiomyopathy
and complete heart block. Another study [20] showed that the
number of nonresponders in the younger patient population was
lower than that in the adult patients, and CRT in this younger group
may help delay heart transplantation, and systemic right ventricle or
single-ventricle patients accounted for approximately 30% of these
subjects.
7. CRT indications
The current suggested indications for CRT in pediatric and CHD
patients [20] are listed in Table 6.
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Table 4
Primary prevention in pediatric and CHD patients [17].
Inherited arrhythmias/electrical myopathies
Long QT Syndrome (LQTS)
Class I: SCD survivors, recurrent syncope, or VT on β-blockers
Strong family SCD history
Medication intolerance
Noncompliance
Short QT Syndrome (SQTS)
Class I: recurrent syncope and malignant arrhythmias
Catecholaminergic Polymorphic VT (CPVT)
Class I: β-blockade alone is insufﬁcient for suppressing VT
Brugada Syndrome (BrS)
Class I:
Spontaneous coved-type electrocardiographic (ECG) pattern and
aborted SCD
Patients with symptoms without a clear etiology
Class IIa:
Asymptomatic patients with either a family history and/or EPS
Symptomatic patients with an ECG pattern elicited only by a Naþ channel
blockade
Class IIb: Asymptomatic patients with both a positive family history and EPS
Cardiomyopathies
Dilated Cardiomyopathy
? Uncontrollable ventricular arrhythmias
Hypertrophic Cardiomyopathy (HCM)
Class I: Cardiac arrest
Class II:
Syncope
Abnormal ECG response to exercise testing
Strong family history/genotype
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Class I: Sustained VT
Congenital Heart Disease
Class IIb: Syncope and inducible sustained VT/VF
High-risk CHD: Aortic stenosis, tetralogy of Fallot, and
d-transposition of the great arteries
Table 5
Effect of CRT pacing according to the type of heart disease [18].
Type of disease N Age (years) Ejection
fraction (EF)
Improvement
(EF units)
Congenital heart disease 73 12.2 (0.5–55.4) 11.9712.9% 39.1731.9
Cardiomyopathy 16 15.8 (0.3–19.6) 12.3713.6% 31.9737.9
Heart block 14 12.5 (0.3–24.3) 16.1712.9% 36.8713.0
p-Value NS NS NS
Table 6
CRT indications [20].
Class IIa
Ventricular dyssynchronization by conventional single ventricular pacing
NYHA class 2
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